Rituximab biosimilar - Genor Biopharma

Drug Profile

Rituximab biosimilar - Genor Biopharma

Alternative Names: GB-241

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Genor Biopharma
  • Developer Genor Biopharma; Nanjing Yoko Biomedical
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma
  • Preclinical Cancer

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma in China (Parenteral) (NCT03003039)
  • 19 Sep 2016 China Food and Drug Administration approves IND application for rituximab biosimilar
  • 25 May 2015 Preclinical trials in Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top